DNDN - Dendreon Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DNDN - Dendreon Corp.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: FDiCianni	8/5/2011 3:39:49 PM
	Read Replies (1) of 751

Interestingly, Johnson & Johnson's (JNJ) Feb 2011,10-k report noted that it acquired Cougar Biotech. in July 2009. From the following excerpt, Cougar was also involved in the development of prostate cancer treatment: "The IPR&D related to the acquisition of Cougar Biotechnology, Inc. was $971 million and is associated with abiraterone acetate, a late stage,first-in-class compound for the treatment of prostate cancer. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 60 — 85% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 23.5%." Perhaps, if DNDN's research and development is advanced enough, DNDN may enter into partnership with JNJ for further support. I did not post a rating for DNDN, yet. I will perform some further research on the company this weekend, and may post a rating later next week. But thanks for bringing up the topic. FDiCianni

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next